BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MUJHU Research Collaboration - ECPv5.12.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MUJHU Research Collaboration
X-ORIGINAL-URL:https://www.mujhu.org
X-WR-CALDESC:Events for MUJHU Research Collaboration
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20220630T090000
DTEND;TZID=UTC:20220701T123000
DTSTAMP:20260428T210119
CREATED:20220613T054124Z
LAST-MODIFIED:20220613T060043Z
UID:6987-1656579600-1656678600@www.mujhu.org
SUMMARY:TB Research Dissemination Workshop
DESCRIPTION:Mbarara Research Centre has extensive experience in TB research and several studies conducted within the Centre have just been completed. This workshop will provide an opportunity to review the latest studies conducted on tuberculosis by Epicentre and its partners to reduce the burden of this disease in Africa. Our Investigator and specialist on paediatric TB\,  Dr. Eric Wobudeya will be a part of the panel discussions during this workshop.  The workshop in English only will be broadcast live on the Epicentre website.\n\n\n\n\n \nDiscover the program and the registration link below\n\n\n\n\n\n\n\nhttps://epicentre.msf.org/en/news/tb-research-dissemination-workshop
URL:https://www.mujhu.org/event/tb-research-dissemination-workshop/
CATEGORIES:Partnerships
ATTACH;FMTTYPE=image/jpeg:https://www.mujhu.org/wp-content/uploads/2022/06/TB-Symposium.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220706T080000
DTEND;TZID=UTC:20220706T120000
DTSTAMP:20260428T210119
CREATED:20220510T075510Z
LAST-MODIFIED:20220613T062348Z
UID:5639-1657094400-1657108800@www.mujhu.org
SUMMARY:SHINE Trial Results Dissemination Meeting
DESCRIPTION:The SHINE Trial Stakeholders Dissemination Meeting\nTreatment length reduced for children with Tuberculosis\nThe SHINE trial exploring the effectiveness of tuberculosis (TB) treatment in children has led to a change in the World Health Organisation’s global guidelines for managing the disease. The research found that the treatment duration for the majority of children with drug-sensitive tuberculosis can be shortened from six to four months\, thereby reducing the burden on families and healthcare systems around the world. \nLead Investigator at the Ugandan site\, Dr. Eric Wobudeya will be meeting with the scientific community in Uganda to share the details of the study and discuss the implications  [date and time of meeting to be announced] . \nResearchers from the MRC Clinical Trials Unit at UCL worked with partners in Uganda\, South Africa\, Zambia and India on the SHINE study\, the first randomised control trial to assess whether children with ‘minimal’ TB could be effectively treated with a shorter course of treatment. \nThe trial involved 1\,204 children aged from two months up to 16 years with non-severe TB\, who were divided randomly into two groups to take either four or six months of treatment with anti-TB medicines. Of the enrolled children\, 11% were living with HIV. All children were followed for 18 months after enrolment to see whether their treatment had been successful. \nThe results clearly showed that children who received the shorter course did as well as those on the standard six-month treatment\, regardless of the age group\, country or HIV status\, with few and similar side effects in both groups. \nThe World Health Organisation Guidelines Development Group reviewed the evidence from SHINE and recommended in August 2021 that presumed drug susceptible TB\, a four-month regimen should be used rather than the standard six-month regimen in children and adolescents with non-severe. \nImportant considerations about how to determine eligibility for the shorter treatment regimen will be described in WHO’s full consolidated guidelines coming out in 2022 and in the operational handbook. \n  \nAbout SHINE\nThe SHINE trial was funded by the Joint Global Health Trials scheme\, including the Department for Health and Social Care\, the Foreign\, Commonwealth and Development Office\, the Medical Research Council and the Wellcome Trust. This UK-funded award is part of the EDCTP2 Programme supported by the European Union. \nAdditional partners included Stellenbosch University\, South Africa; University of Cape Town\, South Africa; National Institute for Research in Tuberculosis\, India; Radboud University Medical Center\, the Netherlands; International Union Against Tuberculosis and Lung Disease\, France; University of Melbourne\, Australia; University of York; Imperial College London and University Hospitals Birmingham. \n  \nAbout MU-JHU Care Ltd\nMU-JHU Care LTD is an HIV research\, care prevention and training facility located on Upper Mulago Hill in the city of Kampala. In 1988\, we started as a collaboration between researchers from Makerere University and Johns Hopkins University in Baltimore\, USA ( US-based researchers were originally based at Case Western Reserve University). Our initial mission was to improve the lives of families infected and affected by HIV through Research\, Care and Training. Up until 2006\, we operated under the name MU-JHU Research Collaboration. In the same year\, we registered as a not-for-profit\, entity in Uganda entitled ‘MU-JHU Care Limited’ with a continuation of the Collaboration’s vision and mission. \nMU-JHU has conducted several landmark research studies\, which have informed global and national policy. These studies paved the way to eliminate mother-to-child HIV transmission and improve maternal and paediatric HIV care. Over the last decade\, MU-JHU has progressively expanded its clinical and implementation science-research portfolio to include: \n\nPrimary HIV prevention\,\nTuberculosis diagnosis and management\,\nPaediatric neuro-development assessment and interventions\,\nBirth-defects surveillance\,\nWomen’s health (including bone health and reproductive health)\,\nThe development of a maternal vaccine platform to assess Group-B Streptococcus and other promising vaccines.\n\nMU-JHU partners with many local and international academic and clinical partners to achieve its mission building on its longstanding Clinical Research Site affiliated with Johns Hopkins University. \nNotes to Editors \nFor more information or to speak to the researchers involved\, please contact \nRomana Brenda Nabbosa\, T: +256 752 307 101\, E: rnabbosa@mujhu.org
URL:https://www.mujhu.org/event/shine-trial-results-dissemination-meeting/
ATTACH;FMTTYPE=image/png:https://www.mujhu.org/wp-content/uploads/2022/05/Picture1-1.png
ORGANIZER;CN="Romana%20B.%20Nabbosa":MAILTO:rnabbosa@mujhu.org
END:VEVENT
END:VCALENDAR